Voucher Does Not Guarantee A Priority Review, FDA Says
Executive Summary
Final guidance on the tropical disease priority review voucher program says FDA will adhere to priority review goals, which allow agency to complete some outside the stated time frame.
You may also be interested in...
Shaping A Shkreli Bill: Voucher Abuse Solution May Stumble On FDA Effects
House bill that would require new clinical studies from sponsor for tropical disease priority review vouchers met with industry concerns about limiting the US agency's flexibility.
Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?
Just as the tulip craze eventually subsided, it appears the pharma industry's infatuation with priority review vouchers also may be waning, as Sarepta sells its voucher for only $125m.
Sponsors May Race For Rare Pediatric Voucher Designations As Deadline Nears
US FDA program's new 2020 sunset could create a bolus of designation requests to ensure they can still get a voucher if it ends.